Your browser is no longer supported. Please, upgrade your browser.
VIR Vir Biotechnology, Inc. daily Stock Chart
Vir Biotechnology, Inc.
Index- P/E- EPS (ttm)-1.26 Insider Own10.30% Shs Outstand114.07M Perf Week-4.69%
Market Cap1.85B Forward P/E- EPS next Y-1.89 Insider Trans0.00% Shs Float100.33M Perf Month-1.69%
Income-137.30M PEG- EPS next Q-0.67 Inst Own63.40% Short Float1.54% Perf Quarter26.54%
Sales10.20M P/S181.84 EPS this Y-567.70% Inst Trans- Short Ratio4.76 Perf Half Y-
Book/sh-23.94 P/B- EPS next Y19.90% ROA- Target Price26.33 Perf Year-
Cash/sh2.81 P/C5.79 EPS next 5Y- ROE- 52W Range11.65 - 29.00 Perf YTD29.30%
Dividend- P/FCF- EPS past 5Y- ROI66.00% 52W High-43.93% Beta-
Dividend %- Quick Ratio7.60 Sales past 5Y- Gross Margin- 52W Low39.57% ATR2.12
Employees217 Current Ratio7.60 Sales Q/Q-70.20% Oper. Margin- RSI (14)43.60 Volatility5.36% 13.00%
OptionableNo Debt/Eq- EPS Q/Q13.80% Profit Margin- Rel Volume0.49 Prev Close16.91
ShortableYes LT Debt/Eq- EarningsMar 03 BMO Payout- Avg Volume325.22K Price16.26
Recom2.40 SMA20-19.41% SMA501.39% SMA2008.42% Volume159,282 Change-3.84%
Feb-04-20Downgrade JP Morgan Overweight → Neutral $25 → $26
Nov-14-19Initiated Robert W. Baird Neutral
Nov-05-19Initiated JP Morgan Overweight $25
Nov-05-19Initiated Goldman Buy $37
Nov-05-19Initiated Cowen Outperform
Nov-05-19Initiated Barclays Overweight $25
Feb-12-20 08:30AM  Vir Biotechnology Identifies Two Antibodies That Bind to the Spike Protein of 2019-nCoV, Newly Named as SARS-CoV-2 GlobeNewswire
Jan-24-20 05:57PM  Coronavirus Stocks Zacks +17.49%
08:55AM  CEPI Grant, Government Aid Drive Coronavirus Focused Biotechs Zacks
Jan-23-20 10:18AM  3 Biotech Stocks Likely to Gain as Coronavirus Spreads Zacks
07:24AM  The Daily Biotech Pulse: Roche Reports Positive SMA Data Readout, Vir Biotech To Work On Virus Treatment Benzinga
Jan-22-20 05:45PM  Vir Biotechnology applying multiple platforms to address public heath risk from Wuhan coronavirus GlobeNewswire
Jan-13-20 08:00AM  Vir Biotechnology to Provide Pipeline Update at 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-09-20 08:00AM  Sundial and Vir Pharmaceuticals Sign Medical Cannabis Supply Agreement for Australian Chronic Pain Clinical Studies CNW Group
Jan-07-20 05:09PM  Vir Biotechnology to Present at 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Nov-19-19 04:15PM  Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2019 Financial Results GlobeNewswire
Nov-07-19 09:16AM  Goldman Sachs Says These 3 Buy-Rated Stocks Are Primed for Growth TipRanks
Oct-25-19 01:16AM  SoftBank's Vision Fund Writedown Can't Be the Half of It Bloomberg
Oct-11-19 05:01PM  Gates-Backed Vir Biotechnology Flops in Trading Debut Bloomberg
12:48PM  Bill Gates-Backed IPO Is Among 2019s Worst Debuts Bloomberg
Oct-10-19 07:41PM  Vir Biotechnology Announces Pricing of Initial Public Offering GlobeNewswire
04:15PM  BioNTech IPO Falls in Trading Debut as Biotech IPO Wave Ebbs Bloomberg
Oct-09-19 08:53AM  Vir Biotech IPO: What You Need To Know Benzinga
Oct-07-19 07:53AM  IPO Outlook For The Week: Banking And Biotech Benzinga
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products for the treatment and prevention of serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus, and VIR-2020 for the prevention of tuberculosis. The company has grant agreement with Bill & Melinda Gates Foundation and National Institutes of Health; option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; collaboration and license agreement Alnylam Pharmaceuticals, Inc.; collaboration, license and option agreement Visterra, Inc.; and license agreement with The Rockefeller University and MedImmune, Inc. It operates in the United States, Oregon, Massachusetts, and Switzerland. The company was founded in 2016 and is headquartered in San Francisco, California.